Novo Nordisk Stock Surges as Biden Advocates Medicare Coverage for Weight-Loss Drugs
Shares of Novo Nordisk jumped 1.3% after President Biden proposed expanding Medicare and Medicaid coverage for weight-loss drugs. Currently covering certain conditions, the changes could become effective in 2026,
Wall Street Journal on MSN16h
Novo Nordisk Says White House Obesity Plan Is Step in Right DirectionNovo Nordisk is encouraged by White House proposals that could support patients using weight-loss drugs, but cautioned ...
Novo Nordisk A/S is cutting back on recruiting in Denmark after reaching the limits of its home country’s labor market in the ...
Novo Nordisk Foundation CEO Mads Krogsgaard Thomsen said only 9 million people are using GLP-1s compared with 1 billion ...
The world’s largest philanthropic fund that ultimately controls Novo Nordisk A/S will ramp up its investments outside of ...
Novo Nordisk will report the topline results from the REDEFINE-1 trial of CagriSema in obese patients before the end of the ...
Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares.
Pharmaceutical company Novo Nordisk has launched its mega-popular weight-loss drug Wegovy in China — but for a tiny fraction ...
Novo Nordisk faces challenges in weight-loss sector, but acquisition and strong diabetes portfolio position it for future ...
More than 200,000 prescriptions for copies of Novo Nordisk's weight-loss drug Wegovy are getting filled by U.S. patients each ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback